Plaintiffs Point To "Tellabs" In Pfizer Securities Suit
The lead plaintiffs in a securities fraud lawsuit against Pfizer Inc. over the drug giant's decision to scrap its highly anticipated cholesterol drug torcetrapib moved to bolster their case Wednesday, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article